Article Text

Download PDFPDF

How to use heat-stable carbetocin and tranexamic acid for the prevention and treatment of postpartum haemorrhage in low-resource settings
  1. Nguyen Toan Tran1,2,
  2. Catrin Schulte-Hillen3,
  3. Sarah Bar-Zeev4,
  4. Agnes Chidanyika4,
  5. Willibald Zeck4
  1. 1The Australian Centre for Public and Population Health Research, Faculty of Health, University of Technology Sydney, Sydney, New South Wales, Australia
  2. 2Faculty of Medicine, University of Geneva, Geneva, Switzerland
  3. 3Humanitarian Office, United Nations Population Fund, Geneva, Switzerland
  4. 4Technical Division, United Nations Population Fund, New York, New York, USA
  1. Correspondence to Professor Nguyen Toan Tran; nguyentoan.tran{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Summary box

  • Heat-stable carbetocin, a uterotonic used for postpartum haemorrhage (PPH) prevention and tranexamic acid, an antifibrinolytic indicated for PPH treatment, are recently recommended medications.

  • The growing number of medications in the PPH prevention and treatment toolkit can challenge policymakers, programme managers and clinicians operating in resource-constrained settings in deciding where and how to invest limited resources to achieve the best possible maternal health outcomes.

  • This paper argues that there is no one-size-fits-all approach to implementing international PPH prevention and treatment guidance.

  • A programmatic strategy tailored to the different levels of maternity care and the availability of skilled providers and cold chain systems is proposed.


The least developed countries, which include those affected by fragility and humanitarian crises, account for 44% of all maternal deaths globally.1 Postpartum haemorrhage (PPH) is a leading cause of maternal mortality in these low-resource settings.2 Because uterine atony accounts for approximately two-thirds of PPH cases, WHO recommends that every woman receives a prophylactic uterotonic immediately after birth to prevent PPH as part of the active management of the third stage of labour.3 4

Some PPH prevention and treatment medicines are well evidenced with a long implementation history, including oxytocin, misoprostol and ergometrine.5 Heat-stable carbetocin (HSC), a uterotonic recommended for PPH prevention and tranexamic acid (TXA), an antifibrinolytic recommended for PPH treatment, were recently added to the core list of reproductive health medicines in the 2019 Model List of Essential Medicines by the WHO.4 6 7 Since 2021, both medications have been made available at public sector pricing through the Product Catalogue of the United Nations Population Fund.8 Unlike heat-sensitive oxytocin or ergometrine, HSC and TXA have the operational advantage of overcoming the logistic costs and challenges inherent to ensuring a cold chain system. Therefore, they could play a critical role in resource-challenged and warm climate settings, where cold chain transport and storage is often not available, which compromises the quality of oxytocin.

The growing number of medications now available in the PPH prevention and treatment toolkit can make it difficult for policymakers, programme managers and clinicians operating in resource-constrained settings to decide where and how to invest limited resources to achieve the best possible health outcomes. In this paper, we focus on pharmacological products for PPH prevention and treatment. We argue that there is no one-size-fits-all approach to preventing and treating PPH and propose a programmatic approach that distinguishes the different levels of maternity care and accounts for existing human and infrastructural resources.

What, where, and how

First, the critical features of HSC and TXA should be understood in light of other established PPH medications. Established medications include oxytocin (a first-line and highly effective injectable uterotonic to prevent and treat PPH in all births), misoprostol (a non-injectable uterotonic for PPH prevention and treatment when there are no trained providers to give injectable uterotonics or oxytocin is not available or of questionable quality) and ergometrine (an injectable uterotonic for PPH prevention and treatment). Table 1 synthesises the main features of these medications. Notably, some uterotonics, for example, oxytocin and misoprostol, have multiple obstetric and gynaecological applications, such as labour induction and augmentation as well as abortion and postabortion care.9 In contrast, HSC and TXA have currently a single obstetric application.

Table 1

Summary of clinical indications and health system requirements of uterotonics and tranexamic acid

HSC is an injectable uterotonic recommended only for PPH prevention. WHO recommends HSC in situations when (1) oxytocin is unavailable or of dubious quality, (2) there is no cold transportation and storage capability, (3) its cost is comparable to that of other effective uterotonics and (4) there is skilled health personnel to inject it.4 TXA is an antifibrinolytic administered intravenously. It is not a uterotonic—therefore, not a uterotonic substitute. TXA is recommended only for PPH treatment in complement with uterotonics as part of the standard PPH treatment package.6 TXA decreases mortality from bleeding in women with PPH, irrespective of the aetiology, be it uterine atony, trauma to the genital tract, retained tissue or clotting disorder.6

Second, prioritising the different medications should align with WHO guidance. For PPH prevention, the following uterotonic hierarchy is recommended: (1) in settings where multiple uterotonics are available, oxytocin (10 IU, intramuscular/intravenous) is the recommended uterotonic in all births, (2) in settings where oxytocin is unavailable (or its quality cannot be guaranteed), the use of other injectable uterotonics (HSC, or, if appropriate, ergometrine/methylergometrine or oxytocin-ergometrine fixed-dose combination) or oral misoprostol is recommended and (3) in settings where skilled health personnel are not present to administer injectable uterotonics, the administration of misoprostol (400 μg or 600 μg orally) by community healthcare workers and lay health workers is recommended.4 As for PPH treatment, (1) intravenous oxytocin is the recommended uterotonic; (2) the early use of intravenous TXA within 3 hours of birth in addition to standard care is recommended in all cases of PPH, regardless of whether the bleeding is due to genital tract trauma or other causes and (3) if intravenous oxytocin is unavailable, or if the bleeding does not respond to oxytocin, the use of intravenous ergometrine, oxytocin-ergometrine fixed-dose, or a prostaglandin drug (including misoprostol) is recommended (ergometrine and oxytocin-ergometrine are not recommended in case of hypertensive disorder).6

Third, these recommendations must, in practice, account for various health system requirements, as summarised in table 1. To help programme managers operationalise the information in table 1, the different health system requirements can be streamlined by focusing on the availability of skilled providers and cold chain transport and storage of 2°C–8°C, two critical constraints often encountered in resource-challenged settings (figure 1).

Figure 1

Practical considerations for procuring and using medicines for PPH prevention and treatment with examples of implementation settings. In blue: 2°C–8°C cold chain transport and storage required (oxytocin and ergometrine). *Heat-stable carbetocin: only in contexts where its cost is comparable to that of other effective uterotonics. §Ergometrine: only in contexts where hypertensive disorders can be safely ruled out before use. PPH, postpartum haemorrhage. ¶For PPH treatment in contexts where there are competent health providers, it is imperative to procure other essential supplies according to the level of care, including crystalloid for fluid replacement and oxygen.

Additionally, figure 1 offers examples of implementation settings, such as comprehensive obstetric care facilities with skilled providers and reliable cold storage (yellow box). Basic emergency obstetric care facilities with skilled providers are subdivided according to the availability (yellow box) or non-availability (orange box) of a consistent electric power source to ensure cold storage. Community-based programmes with the distribution of misoprostol for home births are captured in the grey box.10

Fourth, the reflection on whether HSC and TXA should be integrated into PPH prevention and treatment strategies offers an opportunity to examine the health system and health service gaps that prevent optimal maternal health outcomes. There is, however, no single solution that matches the resources and needs of all the different settings. Therefore, policymakers and programme managers should consider a stepwise programmatic approach to averting maternal deaths. First, existing emergency obstetric care services should undertake a continuous quality improvement process, notably in terms of staff competencies, facility materials and supplies, functional referral mechanisms and performance and accountability. Health facilities should have a working supply chain to avail uterotonics for PPH prevention round-the-clock in addition to essential equipment, medications and up-to-date protocols and job aids for emergency obstetric treatment if PPH or other complications occur. As a complement to uterotonics for PPH treatment, the introduction of TXA for all PPH cases should be considered at this step. This aligns with the WHO guidance and the recommendations of the International Federation of Gynecologists and Obstetricians and the International Confederation of Midwives.6 11 Second, the integration of HSC—and TXA if not done in the previous step—into the health system should be carefully considered at the appropriate level of care. Figure 2 outlines key actions to establishing an enabling policy and programme environment for the introduction of HSC or TXA, or both. Finally, it is important to recognise that contraception remains the most cost-effective intervention to avert maternal deaths globally by preventing unintended pregnancies and allowing healthy timing and spacing of pregnancies.12 Therefore, in conjunction with the previous two steps, health systems should invest in generating demand for family planning and optimising the quality of contraceptive programmes and services (eg, commodities, providers’ clinical skills, provider-client decision-making tools). This includes the first year postpartum when the unmet need for family planning is particularly high.13

Figure 2

Policy and programme considerations for establishing an enabling environment to introduce heat-stable carbetocin or tranexamic acid, or both. PPH, postpartum haemorrhage.


HSC and TXA are recently recommended medications for inclusion in the PPH prevention and treatment toolbox and could potentially play a critical role in decreasing maternal deaths in low-resource settings. Securing their availability in-country should be embedded in a thorough understanding of their clinical indications and the enabling health system environment. Considering whether HSC and TXA should be included in maternal health services provides a new opportunity to engage key national and local stakeholders, including health professionals, to look at the overall health system challenges and opportunities that hinder or support the reduction of maternal mortality and morbidity in general, and that due to PPH specifically.

Data availability statement

There are no data in this work.

Ethics statements

Patient consent for publication

Ethics approval

Not applicable.



  • Handling editor Seye Abimbola

  • Contributors This article was conceived by NTT and CS-H. All authors (NTT, CS-H, SB-Z, AC, WZ) contributed to the development and finalisation of the article.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.